Pharmather (CSE: PHRM) is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals.  Pharmather was founded with a focus on repurposing psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system.

Corporate Presentation

​

---

​Latest Press Releases

December 1, 2020
PharmaTher Expands Research Partnership with University Health Network For Development of Digital Therapeutics Platform

November 24, 2020
PharmaTher Provides Update on its Psychedelic Pharmaceuticals Programs

November 18, 2020
PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI Psychedelic Discovery AI Platform

November 16, 2020
PharmaTher Expands Patent Portfolio with Filing of U.S. Patent for Novel Use of Psilocybin to Treat Cancer

November 11, 2020
Prolific Parkinson's Researcher Dr. Alberto J. Espay Joins Pharmather as Scientific Advisor

October 29, 2020
Leading Parkinson's Researcher Dr. Robert A. Hauser Joins Pharmather as Scientific Advisor

October 27, 2020
Pharmather Files for FDA Orphan Drug Designation for Ketamine in Neuropathic Pain

October 22, 2020
Pharmather Secures Exclusive Rights to Novel Microneedle Delivery Technology for Psychedelic Pharmaceuticals
​
...more press releases

CONNECT WITH US